Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities. / Rasmussen, Thomas; Theilgaard-Mønch, Kim; Hudlebusch, Heidi R; Lodahl, Marianne; Johnsen, Hans E; Dahl, Inger Marie S.

I: British Journal of Haematology, Bind 123, Nr. 2, 2003, s. 253-62.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Rasmussen, T, Theilgaard-Mønch, K, Hudlebusch, HR, Lodahl, M, Johnsen, HE & Dahl, IMS 2003, 'Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.', British Journal of Haematology, bind 123, nr. 2, s. 253-62.

APA

Rasmussen, T., Theilgaard-Mønch, K., Hudlebusch, H. R., Lodahl, M., Johnsen, H. E., & Dahl, I. M. S. (2003). Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities. British Journal of Haematology, 123(2), 253-62.

Vancouver

Rasmussen T, Theilgaard-Mønch K, Hudlebusch HR, Lodahl M, Johnsen HE, Dahl IMS. Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities. British Journal of Haematology. 2003;123(2):253-62.

Author

Rasmussen, Thomas ; Theilgaard-Mønch, Kim ; Hudlebusch, Heidi R ; Lodahl, Marianne ; Johnsen, Hans E ; Dahl, Inger Marie S. / Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities. I: British Journal of Haematology. 2003 ; Bind 123, Nr. 2. s. 253-62.

Bibtex

@article{a75c361054cd11dd8d9f000ea68e967b,
title = "Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.",
abstract = "This study investigated the expression pattern in primary plasma cells (PCs) of putative oncogenes suggested to be involved in multiple myeloma (MM) development. cDNA archives were generated by global reverse transcription polymerase chain reaction from CD38++/CD19-/CD56-/++ aberrant PCs of a prospective cohort of 96 subjects, including healthy individuals, patients with monoclonal gammopathies of undetermined significance (MGUS), MM and MM with extramedullary manifestations (ExMM). The cDNA archives were analysed quantitatively for expression of the cyclin D1, fibroblast growth factor receptor 3 (FGFR3), C-MYC, C-MAF and cyclin D3 oncogenes. In addition, all patients were screened for IGH-MMSET hybrid transcripts. None of the analysed oncogenes was randomly distributed. C-MYC and cyclin D3 expression increased at the extramedullary transformation stage. Furthermore, C-MYC and cyclin D3 expression in CD56+ MM was similar to MGUS, whereas CD56- MM was similar to ExMM. FGFR3/IGH-MMSET was only observed among CD56+ MM patients, whereas an increased frequency of C-MAF dysregulation was seen among CD56- MM. High cyclin D1 expression levels were identified at similar frequencies at all stages, whereas the frequency of patients with low cyclin D1 levels increased during MM development. These data support the stepwise transformation model accumulating genetic alterations and proliferative capacity during MM initiation and development resulting in different clinical entities.",
author = "Thomas Rasmussen and Kim Theilgaard-M{\o}nch and Hudlebusch, {Heidi R} and Marianne Lodahl and Johnsen, {Hans E} and Dahl, {Inger Marie S}",
note = "Keywords: Cell Transformation, Neoplastic; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 4; Cyclin D1; DNA, Complementary; DNA, Neoplasm; Disease Progression; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oncogene Proteins; Oncogenes; Paraproteinemias; Plasma Cells; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic",
year = "2003",
language = "English",
volume = "123",
pages = "253--62",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.

AU - Rasmussen, Thomas

AU - Theilgaard-Mønch, Kim

AU - Hudlebusch, Heidi R

AU - Lodahl, Marianne

AU - Johnsen, Hans E

AU - Dahl, Inger Marie S

N1 - Keywords: Cell Transformation, Neoplastic; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 4; Cyclin D1; DNA, Complementary; DNA, Neoplasm; Disease Progression; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oncogene Proteins; Oncogenes; Paraproteinemias; Plasma Cells; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic

PY - 2003

Y1 - 2003

N2 - This study investigated the expression pattern in primary plasma cells (PCs) of putative oncogenes suggested to be involved in multiple myeloma (MM) development. cDNA archives were generated by global reverse transcription polymerase chain reaction from CD38++/CD19-/CD56-/++ aberrant PCs of a prospective cohort of 96 subjects, including healthy individuals, patients with monoclonal gammopathies of undetermined significance (MGUS), MM and MM with extramedullary manifestations (ExMM). The cDNA archives were analysed quantitatively for expression of the cyclin D1, fibroblast growth factor receptor 3 (FGFR3), C-MYC, C-MAF and cyclin D3 oncogenes. In addition, all patients were screened for IGH-MMSET hybrid transcripts. None of the analysed oncogenes was randomly distributed. C-MYC and cyclin D3 expression increased at the extramedullary transformation stage. Furthermore, C-MYC and cyclin D3 expression in CD56+ MM was similar to MGUS, whereas CD56- MM was similar to ExMM. FGFR3/IGH-MMSET was only observed among CD56+ MM patients, whereas an increased frequency of C-MAF dysregulation was seen among CD56- MM. High cyclin D1 expression levels were identified at similar frequencies at all stages, whereas the frequency of patients with low cyclin D1 levels increased during MM development. These data support the stepwise transformation model accumulating genetic alterations and proliferative capacity during MM initiation and development resulting in different clinical entities.

AB - This study investigated the expression pattern in primary plasma cells (PCs) of putative oncogenes suggested to be involved in multiple myeloma (MM) development. cDNA archives were generated by global reverse transcription polymerase chain reaction from CD38++/CD19-/CD56-/++ aberrant PCs of a prospective cohort of 96 subjects, including healthy individuals, patients with monoclonal gammopathies of undetermined significance (MGUS), MM and MM with extramedullary manifestations (ExMM). The cDNA archives were analysed quantitatively for expression of the cyclin D1, fibroblast growth factor receptor 3 (FGFR3), C-MYC, C-MAF and cyclin D3 oncogenes. In addition, all patients were screened for IGH-MMSET hybrid transcripts. None of the analysed oncogenes was randomly distributed. C-MYC and cyclin D3 expression increased at the extramedullary transformation stage. Furthermore, C-MYC and cyclin D3 expression in CD56+ MM was similar to MGUS, whereas CD56- MM was similar to ExMM. FGFR3/IGH-MMSET was only observed among CD56+ MM patients, whereas an increased frequency of C-MAF dysregulation was seen among CD56- MM. High cyclin D1 expression levels were identified at similar frequencies at all stages, whereas the frequency of patients with low cyclin D1 levels increased during MM development. These data support the stepwise transformation model accumulating genetic alterations and proliferative capacity during MM initiation and development resulting in different clinical entities.

M3 - Journal article

C2 - 14531906

VL - 123

SP - 253

EP - 262

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -

ID: 5070836